Skip to main content
PMC home page
Gut logoLink to Gut
. 1973 Aug;14(8):637–641. doi: 10.1136/gut.14.8.637

The metabolism of salicylazosulphapyridine in ulcerative colitis

II The relationship between metabolites and the progress of the disease studied in outpatients

PMCID: PMC1412752  PMID: 18668841

Abstract

Serum concentrations of salicylazosulphapyridine (SASP), sulphapyridine (SP), and 5-aminosalicylic acid (5-ASA) were measured in 64 outpatients with ulcerative colitis. About 90% of the patients in remission had serum total SP concentrations above 20 μg/ml. Seven patients, however, had active disease despite a serum total SP concentration > 20 μg/ml. The SASP and the individual SP metabolites did not show any correlation with the disease state. Three g per day seems to be the most effective dose. Plain and enteric-coated tablets produced similar concentrations at equivalent dosage. Side effects due to SASP were frequent in patients who had a total SP concentration > 50 μg/ml of serum.

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  2. Das K. M., Eastwood M. A., Macmanus J. P., Sircus W. Salazopyrin metabolism in ulcerative colitis. Gut. 1972 Oct;13(10):840–840. [PubMed] [Google Scholar]
  3. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hansson K. A. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 May;10(2):153–155. [PubMed] [Google Scholar]
  5. Hansson K. A., Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 Mar;10(1):87–92. [PubMed] [Google Scholar]
  6. Jalan K. N., Prestcott R. F., Sircus W., Card W. I., McManus J. P., Falconer C. W., Small W. P., Smith A. N., Bruce J. Ulcerative colitis. A clinical study of 399 patients. J R Coll Surg Edinb. 1971 Nov;16(6):338–351. [PubMed] [Google Scholar]
  7. LENNARD-JONES J. E., MISIEWICZ J. J., CONNELL A. M., BARON J. H., JONES F. A. PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. Lancet. 1965 Jan 23;1(7378):188–189. doi: 10.1016/s0140-6736(65)90973-6. [DOI] [PubMed] [Google Scholar]
  8. MOERTEL C. G., BARGEN J. A. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med. 1959 Nov;51:879–889. doi: 10.7326/0003-4819-51-5-879. [DOI] [PubMed] [Google Scholar]
  9. Peppercorn M. A., Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555–562. [PubMed] [Google Scholar]
  10. Sandberg M., Hansson K. A. Determination of salicylazosulphapyridine in biological materials. Acta Pharm Suec. 1973 May;10(2):107–110. [PubMed] [Google Scholar]
  11. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES